Table 3. Association between ELAC2 staining and prostate cancer phenotype in the TMPRSS2: ERG fusion positive subset.

Parameter	Evaluable	ELAC2 nuclear staining (%)				P value
	(n)	Negative	Weak	Moderate	Strong
Total	3 624	24.6	28.9	35.6	10.8
Tumor stage
pT2	2 130	25.0	29.2	35.4	10.4	0.2855
pT3a	981	22.6	29.7	36.4	11.3
pT3b	475	27.2	27.2	34.5	11.2
pT4	21	23.8	14.3	33.3	28.6
Gleason grade
≤3+3	770	33.9	27.7	30.9	7.5	<0.0001
3+4	2 064	22.4	29.1	37.4	11.1
3+4 Tert.5	110	17.3	30.9	39.1	12.7
4+3	358	23.7	28.2	35.2	12.8
4+3 Tert.5	185	17.3	29.7	39.5	13.5
≥4+4	135	24.4	32.6	29.6	13.3
Lymph node metastasis
N0	2 085	22.0	27.1	37.9	12.9	0.1541
N+	232	22.4	33.6	31.9	12.1
Preoperative PSA level (ng/ml)
<4	496	24.4	29.0	35.5	11.1	0.9981
4–10	2 184	24.4	28.8	35.9	11.0
10–20	660	25.2	28.8	35.9	10.2
>20	234	26.1	30.3	33.3	10.3
Surgical margin
Negative	2 818	24.8	28.7	35.5	11.0	0.8555
Positive	738	24.3	30.1	35.5	10.2